Beyond The Printed Page

  1. A Primer On Biopharma Manufacturing From Bristol-Myers Squibb’s Lou Schmukler

    Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, explains some of the nuances between small and large molecule drug manufacturing. 

  2. Amgen’s Acquisition Of Onyx Pharmaceuticals — Through The Eyes Of Tony Coles

    Tony Coles, M.D., former CEO of Onyx Pharmaceuticals, provides his perspective on Amgen’s $9.7 billion acquisition of Onyx.

  3. Tony Coles On The Importance Of Courage In Leadership

    Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, discusses the decision to acquire Proteolix for $800 million when serving as the CEO of Onyx Pharmaceuticals.

  4. Tony Coles On The Passing Of A Scientific Icon

    Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, talks about the loss of Susan Lindquist, one of the company’s cofounders.

  5. Sanofi’s Digital Health Guru On Joint Ventures And Finding Top Talent

    Ameet Nathwani, M.D., EVP of Sanofi’s medical function, discusses digital health joint venture with Verily Life Sciences, and good places to look for digital health top talent.

  6. Small Clinical Trials Lead To Big Results

    In this preview of our July 2018 issue, the CEO of Sage Therapeutics, Jeff Jonas, M.D., elaborates on the company’s approach to developing small clinical trials.

  7. What Is “A Return To The Basics Of Science?”

    Sage Therapeutics’ CEO Jeff Jonas, M.D., discusses what he means by a “return to the basics of science” at his company.

  8. Pending Depression Breakthroughs From The Sage Therapeutics’ CEO

    Jeff Jonas, M.D., CEO of Sage Therapeutics, discusses some of the challenges of launching a product that could change the paradigm of treating postpartum depression (PPD).

  9. Allergan, Biogen, And GSK — 3 Questions To 3 Manufacturing Experts At 3 Companies

    Three manufacturing executives from three different companies (i.e., Allergan, Biogen, and GSK) tackle questions on trends, regions, and the future of biopharmaceutical manufacturing.

  10. What Will Have A Big Impact On Your Biopharma Manufacturing Organizations?

    Four biopharma manufacturing executives disclose what they are doing at their organization that will have a big impact on manufacturing operations in 2018 and beyond.